hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 19:59:00 - browse：6

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Boston competes with Raleigh

WSS

5 takeaways from STAT's examination of Zynex Medical

New report analyzes digital physical therapy solutions' effectiveness

Venture capital firm's plans to take over Akron hospital face hurdles

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Medicare Advantage insurers face 0.2% cut to 2025 payments

The Affordable Care Act has saved billions in health care costs

hotspot

hotspot

entertainment

Alkermes shareholders re

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Medical records are filled with copy

ALS patient reclaims some autonomy thanks to wearable 'robot'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readers discuss the intersection of pregnancy and addiction

Activists slam private health insurers over coverage restrictions

Syphilis numbers in the United States reach record heights

Hollywood unions extend contract negotiations for actors

Deposition: Sackler embraced plan to conceal OxyContin’s strength

explore

Philips to halt sales of sleep apnea machines in U.S.

Curing rare childhood diseases will falter unless Congress steps up

NIH tests clinical research in primary care with $30 million program

Merck, Johnson & Johnson CEOs will testify on high drug prices

Statins may not be needed by millions of people, study suggests

STAT Virtual Event: ASCO Recap, Live!

hotspot

hotspot

entertainment

focus